Sol-Gel Technologies Ltd.

NasdaqGM:SLGL Stock Report

Market Cap: US$19.5m

Sol-Gel Technologies Valuation

Is SLGL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SLGL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SLGL ($0.7) is trading below our estimate of fair value ($54.1)

Significantly Below Fair Value: SLGL is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SLGL?

Other financial metrics that can be useful for relative valuation.

SLGL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does SLGL's PS Ratio compare to its peers?

The above table shows the PS ratio for SLGL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average13.6x
IGXT IntelGenx Technologies
26.7xn/aUS$27.8m
TXMD TherapeuticsMD
19.5xn/aUS$23.4m
RDHL RedHill Biopharma
2.2xn/aUS$14.6m
LPCN Lipocine
6x66.4%US$28.5m
SLGL Sol-Gel Technologies
12.5x60.1%US$19.5m

Price-To-Sales vs Peers: SLGL is good value based on its Price-To-Sales Ratio (12.5x) compared to the peer average (13.6x).


Price to Earnings Ratio vs Industry

How does SLGL's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.9%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.9%
n/an/an/a
No more companies

Price-To-Sales vs Industry: SLGL is expensive based on its Price-To-Sales Ratio (12.5x) compared to the US Pharmaceuticals industry average (3.1x).


Price to Sales Ratio vs Fair Ratio

What is SLGL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SLGL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SLGL's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SLGL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.69
US$8.00
+1,060.3%
12.5%US$9.00US$7.00n/a2
May ’25US$0.78
US$8.00
+923.0%
12.5%US$9.00US$7.00n/a2
Apr ’25US$1.00
US$8.00
+703.9%
12.5%US$9.00US$7.00n/a2
Mar ’25US$1.13
US$8.00
+606.4%
12.5%US$9.00US$7.00n/a2
Feb ’25US$1.50
US$8.00
+433.3%
12.5%US$9.00US$7.00n/a2
Jan ’25US$1.11
US$8.00
+624.0%
12.5%US$9.00US$7.00n/a2
Dec ’24US$1.33
US$8.00
+501.5%
12.5%US$9.00US$7.00n/a2
Nov ’24US$1.30
US$10.50
+707.7%
14.3%US$12.00US$9.00n/a2
Oct ’24US$1.63
US$10.50
+544.2%
14.3%US$12.00US$9.00n/a2
Sep ’24US$2.75
US$10.50
+281.8%
14.3%US$12.00US$9.00n/a2
Aug ’24US$3.89
US$14.00
+259.9%
35.7%US$19.00US$9.00n/a2
Jul ’24US$2.99
US$14.50
+384.9%
31.0%US$19.00US$10.00n/a2
Jun ’24US$3.44
US$14.50
+321.5%
31.0%US$19.00US$10.00n/a2
May ’24US$3.62
US$11.50
+217.7%
48.8%US$19.00US$5.50US$0.783
Apr ’24US$3.88
US$11.50
+196.4%
48.8%US$19.00US$5.50US$1.003
Mar ’24US$4.35
US$12.50
+187.4%
44.2%US$19.00US$5.50US$1.133
Feb ’24US$5.04
US$12.50
+148.0%
44.2%US$19.00US$5.50US$1.503
Jan ’24US$4.56
US$12.50
+174.1%
44.2%US$19.00US$5.50US$1.113
Dec ’23US$4.67
US$12.50
+167.7%
44.2%US$19.00US$5.50US$1.333
Nov ’23US$5.05
US$14.50
+187.1%
47.0%US$22.00US$5.50US$1.303
Oct ’23US$5.02
US$19.00
+278.5%
15.8%US$22.00US$16.00US$1.632
Sep ’23US$6.02
US$18.00
+199.0%
15.7%US$22.00US$16.00US$2.753
Aug ’23US$5.79
US$17.67
+205.1%
13.3%US$21.00US$16.00US$3.893
Jul ’23US$4.34
US$17.67
+307.1%
13.3%US$21.00US$16.00US$2.993
Jun ’23US$5.91
US$16.75
+183.4%
15.4%US$21.00US$14.00US$3.444
May ’23US$7.10
US$17.00
+139.4%
15.0%US$21.00US$14.00US$3.624

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.